More anti-PD-1 (Camrelizumab, Cemiplimab, Sintilimab, Spartalizumab) as well as anti-PD-L1 (Atezolizumab, Avelumab, Durvalumab) monoclonal antibodies are indicated for treatment of cancers of different origin.5, 6, 7 Although the prerequisite biomarker for predicting immune checkpoint inhibitors response is tissue PD-L1 expression, association of sPD-L1 serum level with treatment outcomes is under investigation. This evidence concerns the gene SPDL1 and cancer.